Tulane University COVID Antibody and Immunity Network (TUCAIN)

杜兰大学新冠病毒抗体和免疫网络 (TUCAIN)

• 批准号: 10688376
• 负责人: JAMES E Robinson
• 金额: $ 192.04万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10688376
• 关键词: 2019-nCoV; Address; Advanced Development; Algorithms; Antibodies; Antibody Response; Antibody-mediated protection; Applied Research; Big Data; Blood; Blood specimen; COVID-19; COVID-19 patient; COVID-19 survivors; COVID-19 treatment; Cellular Immunity; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Data; Collection; Data; Data Set; Development; Diagnosis; Disease; Evolution; Funding; Goals; Humoral Immunities; Immune response; Immunity; Immunocompromised Host; Immunologics; Individual; Infection; Knowledge; Longevity; Louisiana; Malignant Neoplasms; Measures; Medicine; Memory; Methods; Mission; Pathogenesis; Pathogenicity; Patient-Focused Outcomes; Patients; Persons; Plasma; Recurrence; Reporting; Research; Risk; SARS-CoV-2 immunity; Serology test; Serum; Special Population; Survivors; Systems Biology; Technology; Therapeutic; Time; Universities; Vaccines; Viral; Viral Hemorrhagic Fevers; Virus; base; biobank; cell mediated immune response; cohort; convalescent plasma; coronavirus disease; human pathogen; improved; insight; longitudinal analysis; mortality; neutralizing antibody; novel; personalized medicine; prevent; programs; public health emergency; response; screening; therapeutic evaluation; treatment strategy

Overall Summary The SARS-CoV-2 virus, the causative agent of COVID-19, has infected a reported 13,810,247 persons globally as of July 16, 2020 with a mortality rate of 4.2%. In the State of Louisiana, over 7.3% of the 86,411 COVID-19 cases involve people living with cancer. Theoretically, convalescent plasma contains protective antibodies that neutralizes virus and mitigates its pathogenic effects. Yet, there remains a large gap in our understanding of the mechanisms that drive humoral and cellular immune responses and how these responses correlate with disease course and protection as well as the durability of those responses. Furthermore, there is a need for serological assays that measure these responses accurately for serodiagnosis and as correlates of immunity and protection. Without this knowledge, the true efficacy of convalescent plasma as therapy for COVID-19 and our understanding of the humoral immune response to SARS-CoV-2, especially in immunocompromised patients, will remain unknown. The overall goal of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) is to characterize this response with respect to functionality and durability. We will achieve this goal by investigating the following broad specific aims: (1) Characterize the evolution, function and longevity of the humoral immune response to COVID-19. (2) Identify cell mediated immune responses that contribute to durable or short-lived humoral immunity to SARS CoV-2. (3) Correlate protective and potentially pathogenic immune responses to the clinical course of hospitalized COVID-19 patients. We will achieve these goals by studying a diverse cohort of COVID-19 survivors and minimally sick seroconverters, including a large cohort of patients with malignancies. Using serial blood collections, we will apply several immunological technologies to study the evolution and durability of the immune response over time. We will also correlate these responses to patient outcomes and disease pathogenesis using a “big data”, systems biology approach. An approach, such as the one we propose, will allow us to determine if COVID-19 survivors develop long-term, antibody-based protection and we can confirm if convalescent plasma has therapeutic potential. This research will allow us to identify new targets for medicines and vaccines, inform personalized treatment strategies such as those required by immunocompromised patients with cancer, and to provide novel immunological algorithms applicable to a wide range of human pathogens.

总结 SARS-COV-2病毒是Covid-19的病因，已感染了全球13,810,247人 截至2020年7月16日，死亡率为4.2％。在路易斯安那州，在86,411 Covid-19中超过7.3％ 病例涉及癌症患者。理论上的康复等离子体包含受保护的抗体 中和病毒并减轻其致病作用。然而，我们对 驱动体液和细胞免疫复杂的机制以及这些反应如何与疾病相关 课程和保护以及这些响应的耐用性。此外，需要血清学 准确地测量这些反应的测定法和作为免疫力和保护的相关性。 没有这些知识，康复等离子体作为Covid-19和我们的疗法的真正效率 了解SARS-COV-2的体液免疫响应，特别是在免疫功能低下的患者中， 将保持未知。 杜兰大学康复抗体和免疫网络（Tucain）的总体目标是 在功能和耐用性方面表征此响应。我们将通过调查实现这一目标 以下广泛的特定目的：（1）表征体液免疫的演变，功能和寿命 对COVID-19的反应。 （2）确定细胞介导的免疫反应，有助于耐用或短暂的寿命 SARS COV-2的体液免疫学。 （3）将受保护的并潜在的致病性免疫反应与 住院Covid-19患者的临床过程。我们将通过研究潜水员队列来实现这些目标 COVID-19-19，生存和微小的血清抗体，包括大量恶性患者。 使用串行血液收集，我们将应用几种免疫技术来研究进化和 免疫反应的持续时间随着时间的流逝。我们还将将这些反应与患者的结果相关联 使用“大数据”，系统生物学方法的疾病发病机理。一种方法，例如我们提出的一种方法 将使我们能够确定COVID-19是否生存是否发展为长期，基于抗体的保护，我们可以 确认康复血浆是否具有治疗潜力。这项研究将使我们能够确定 药物和疫苗，为个性化治疗策略提供信息，例如 免疫功能低下的癌症患者，并提供适用于广泛的新型免疫学算法 人类病原体范围。